Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure

2005 ◽  
Vol 61 (3) ◽  
pp. 209-214 ◽  
Author(s):  
Ragnar Watz ◽  
Ann-Britt Ekstrand ◽  
Victoria Engelbrektson ◽  
Björn Beermann
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Chronic Heart Failure ◽  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Angiotensin Ii Antagonists ◽  
Unselected Group

Heart failure

2012 ◽  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Signs And Symptoms ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Converting Enzyme Inhibitors

Introduction 368Forms of heart failure 370Causes and precipitants 372Signs and symptoms 374Investigations 378Management of heart failure 382Diuretics in heart failure 386Angiotensin-converting enzyme inhibitors for heart failure 390Angiotensin II receptor antagonists for heart failure 392Beta-blockers for heart failure ...

ACE Inhibition versus Angiotensin-II Antagonism in Heart Failure

2000 ◽  
Vol 8 (2) ◽  
pp. 195-203 ◽  
Author(s):  
Surendra Kumar ◽  
Dharm Raj Maurya ◽  
Mahesh Chandra
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Ace Inhibition ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Angiotensin Ii Antagonists ◽  
Clinical Benefits

Heart failure is becoming increasingly frequent. Once diagnosed, 5-year survival is less than 50% and a substantial percentage of patients (25% to 50%) die suddenly. Angiotensin-converting enzyme inhibitors are the only agents shown to reduce mortality in heart failure. All angiotensin-converting enzyme inhibitors appear to have similar clinical benefits in heart failure. Therapy should be started with a low dose and titrated up to the target dosage in major trials. Although angiotensin-I receptor antagonists provide more complete inhibition of angiotensin-II effects, they have not been found to be superior to long-acting angiotensin-converting enzyme inhibitors in reducing morbidity and mortality in heart failure. Therefore, in current clinical practice, angiotensin-II antagonists should be used as an alternative to angiotensin-converting enzyme inhibitors when the latter are not tolerated. The combined use of angiotensin-converting enzyme inhibitors and angiotensin-II antagonists is not currently recommended in the treatment of heart failure.

scholarly journals Epidemiology and treatment of chronic heart failure; use of bisoprolol

2013 ◽  
Vol 154 (44) ◽  
pp. 1731-1734
Author(s):  
Viktor Nagy
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15–20% of subjects over 80 years of age. The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists. Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure. However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure. The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies. Orv. Hetil., 154 (44), 1731–1734.

Sign in / Sign up

Export Citation Format

Share Document